



Published in final edited form as:

Nat Cell Biol. 2014 February ; 16(2): 191–198. doi:10.1038/ncb2902.

N⁶-methyladenosine modification destabilizes developmental regulators in embryonic stem cells

Yang Wang¹, Yue Li², Julia I. Toth¹, Matthew D. Petroski¹, Zhaolei Zhang^{2,3}, and Jing Crystal Zhao^{1,*}

¹Tumor Initiation and Maintenance Program, NCI-designated Cancer Center, Sanford Burnham Medical Research Institute, San Diego, CA, 92037, USA

²Department of Computer Science, The Donnelly Centre, University of Toronto, Toronto, M5S 3G4, Canada

³Department of Molecular Genetics, Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, Toronto, M5S 3G4, Canada

Abstract

Historically, N⁶-methyladenosine (m⁶A) has been identified as the most abundant internal modification of messenger RNA (mRNA) in eukaryotes ¹. Its mammalian function remained unknown until recently, when it was reported that thousands of mammalian mRNAs and long noncoding RNAs (lncRNAs) show m⁶A modification ^{2,3} and that m⁶A demethylases are required for mammalian energy homeostasis and fertility ^{4,5}. As yet, the identity of m⁶A methyltransferases (MTase) and the molecular mechanisms regulated by m⁶A remains unclear. Here, we show that two proteins, the putative m⁶A MTase, methyltransferase-like 3 (Mettl3) ⁶, and a related but uncharacterized protein Mettl14, function synergistically to control m⁶A formation in mammalian cells. Since m⁶A modification is involved in cell fate determination in yeast ^{7,8} and embryo development in plant ^{9,10}, we knocked down *Mettl3* and *Mettl14*, respectively, in mouse embryonic stem cells (mESCs). The resulting cells displayed equivalent phenotypes characterized by lack of m⁶A RNA methylation and lost self-renewal capability. We also observed that a large number of transcripts, including many encoding developmental regulators, showed m⁶A methylation inversely correlated with mRNA stability and gene expression. Further analysis suggested that some of these effects were mediated through Human antigen R (HuR) and microRNA pathways. Overall our work provides first experimental evidence of mammalian m⁶A MTases and reveals a previously unknown gene regulatory mechanism operating in mESCs through m⁶A methylation. This mechanism is required to keep mESCs at their ground state and may be relevant to thousands of mRNAs and lncRNAs in various cell types.

Reprints and permissions information are available at www.nature.com/reprints.

*Correspondence and requests for materials should be addressed at czhao@sanfordburnham.org.

Author Contributions Y.W. generated Mettl3 and Mettl14 knockdown mESC lines, and using these lines, designed, performed, and analyzed most experiments, except meRIP, RIPs, and EMSAs. meRIP, RIPs, and EMSAs were performed by Y.W. and J.C.Z. Y.L. performed all bioinformatics analysis under the supervision of Z.Z. J.I.T. and M.D.P. purified luciferase, Mettl3 and/or Mettl14 proteins from baculovirus-infected Sf9 insect cells. J. C. Z. formulated, analyzed, and directed the study and wrote the paper.

RNA and DNA MTases share structural motifs required to transfer methyl groups from S-adenosyl-L-methionine (SAM) to nucleic acid. Previously, two mammalian m⁶A MTases, *Mettl3* and *Mettl14*, are predicted computationally based on conservation of the SAM binding domain and phylogenetic analysis^{11,12}. *Mettl3* purified from HeLa cell nuclear extracts functions as a putative MTase⁶, while *Mettl14* remains uncharacterized. A recent study reported altered RNA splicing in *Mettl3* knockdown HeLa cells³, but as yet no direct evidence links *Mettl3* to m⁶A formation.

An NCBI Blast Protein sequence analysis revealed greater than 35% sequence homology of the MTase domain between *Mettl3* and *Mettl14* (Fig.1A), suggesting that both are MTases. To test this possibility we constructed shRNAs targeting *Mettl3* or *Mettl14* and generated mESC lines harboring efficient knockdown (kd) of each (Fig.1B). We then used two independent methods to determine m⁶A levels in kd mESCs. First, immunoblotting of RNA samples using a highly specific α -m⁶A antibody^{2,3} indicated decreased m⁶A levels in both *Mettl3* kd and *Mettl14* kd versus control cells (Fig.1C). We then used Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) to quantify m⁶A/A ratios and observed a 60-70% decrease in m⁶A levels in each kd line relative to controls (Fig.1D), suggesting that both proteins mediate m⁶A formation *in vivo*. mESCs expressing additional shRNAs targeting *Mettl3* or *Mettl14* were generated to control for shRNA off-target effects (Supplementary Fig.1A) and similarly decreased m⁶A levels were detected in all kd clones (Supplementary Fig.1B). We then undertook a direct methylation assay by incubating an RNA probe exhibiting four repeats of the canonical m⁶A methylation motif (GGACU) with equal amounts of luciferase, *Mettl3* and/or *Mettl14* proteins (Fig.1E and Supplementary Fig. 1C) purified from HEK293 cells in the presence of [³H] SAM and assessed [³H] methyl transfer. The RNA probe incubated with control luciferase protein showed no increase in [³H] levels. However, 1.5-, 3.5-, and > 27-fold increases in [³H] levels were detected in probes incubated with *Mettl3*, *Mettl14*, and *Mettl3* plus *Mettl14* (Fig. 1F), respectively. Thin layer chromatography analysis (TLC) confirmed that methylated nucleotides were m⁶A (Fig. 1G and Supplementary Fig.1D). To exclude the possibility that the enzymatic activities was due to promiscuously co-purified mammalian proteins, we performed methylation assays using proteins purified from baculovirus-infected Sf9 insect cells. We found *Mettl3* or *Mettl14* difficult to be purified alone but easily co-purified when co-expressed. As shown in Supplementary Fig.1E, *Mettl3* was specifically pulled down by *Mettl14* but not luciferase, suggesting a strong interaction between *Mettl3* and *Mettl14*. Importantly, *Mettl3*+ *Mettl14* exhibited high m⁶A MTase activity (Supplementary Fig.1F and Supplementary Fig.1G), demonstrating that MTase activities detected from HEK293 purified proteins are indeed from *Mettl* proteins. To further assess specificity, we undertook kd analysis targeting *Mettl4*, a gene of the *Mettl3* and *Mettl14* superfamily, and detected no change in m⁶A levels despite high kd efficiency (Supplementary Fig.1H and 1I). These studies show that both *Mettl3* and *Mettl14* exhibit *in vitro* and *in vivo* MTase activity and suggest that they function synergistically.

We next undertook a genome-wide search for RNA substrates showing decreased m⁶A methylation in kd mESCs by coupling m⁶A immunoprecipitation with high-throughput sequencing (meRIP-seq)^{2,3}. Twelve libraries, including replicates of a pair of input and

meRIP samples from scramble controls, Mettl3 kd, and Mettl14 kd cells, were sequenced. Approximately 38 – 55 million reads were generated for each type of library and high Pearson correlation coefficients (cc) ($R \geq 0.97$) were obtained among replicates, suggesting high library reproducibility. 3.8 to 6.7 million distinct reads uniquely aligned to the mouse mm10 reference genome were used to detect m⁶A sites, which were identified by MACS peak-calling software. A stringent cutoff threshold of False Discovery Rate (FDR) of <10% was used to obtain high confidence peaks. After combining replicate libraries, 8,645, 6,667, and 6,159 high confidence peaks from scramble, Mettl3 kd, and Mettl14 kd cells, respectively, remained for analysis. Overall, 4,766 genes in Mettl3 kd and 4,749 in Mettl14 kd cells showed significantly decreased transcript m⁶A levels relative to controls. For example, the Sox17 mRNA methylation peak was detected only in the scramble control but not in Mettl3 or Mettl14 kd cells (Fig.2A, Supplementary Table1). Interestingly, Mettl3 and Mettl14 targets overlapped substantially (Fig.2B), supporting our hypothesis that they synergize. To examine potential interaction *in vivo*, we performed co-immunoprecipitation (co-IP) of both endogenous and flag-tagged Mettl3 and Mettl14. All experiments demonstrated robust and specific interaction of both proteins (Fig. 2C and Supplementary Fig.2A). To determine whether Mettl3 or Mettl14 homodimerize, flag- and HA-tagged Mettl3 or Mettl14 were co-expressed in HEK293 cells. No HA-Mettl3 was pulled down by flag-Mettl3 (Supplementary Fig.2B), indicating that Mettl3 does not homodimerize. Similar results were observed for Mettl14 (Supplementary Fig.2B). We then asked whether these proteins regulated each other's expression. Strikingly, we observed an almost total loss of Mettl3 protein in Mettl14 kd cells (Fig. 2D), despite a small decrease in Mettl3 RNA (Fig. 2E). Comparable results were observed for Mettl14 protein and RNA in Mettl3 kd cells (Fig. 2D and 2E), suggesting that Mettl3 and Mettl14 stabilize each other at the protein levels. Finally GO analysis indicated that Mettl3 and Mettl14 targets regulate transcription, RNA splicing, chromatin modification, programmed cell death, and cell fate determination (Fig. 2F). Overall, these results suggest that Mettl3 and Mettl14 regulate m⁶A modification of a significant number of mRNAs in mammalian cells, possibly by participating in a complex.

Phenotypically, Mettl3 or Mettl14 kd mESC colonies were flatter and less compact than control colonies (Fig. 3A and Supplementary Fig.3A), and cell proliferation rate decreased (Fig. 3B). Alkaline phosphatase (AP) staining showed that only 20-30% of mESC colonies were AP-positive in kd cells relative to scramble controls (Fig. 3C and Supplementary Fig. 3B). More quantitative FACS analysis of AP positive cells showed that 50.8% of control cells exhibit high AP levels, while Mettl3 and Mettl14 kd cells showed 32.2% and 37.7%, respectively. SSEA-1 FACS analysis revealed no difference between kd (99.7% and 96.5% for Mettl3 and Mettl14, respectively) and control (99.3%) cells, indicating that kd cells differ from terminal differentiated cells and maintain some stem cell features. To understand these outcomes at the molecular level, we carried out microarray analysis of Mettl3 kd and Mettl14 kd mESCs and found that both shared gene expression profiles distinct from control cells (Fig. 3D). RT-qPCR analysis indicated that most pluripotency factors were downregulated in Mettl3 or Mettl14 kd cells relative to controls (Left panels of Fig. 3E, and Supplementary Fig.3C), while some developmental regulators were significantly upregulated (Right panels of Fig. 3E and Supplementary Fig.3C). Similar results were obtained from mESCs transfected for 48 hrs with siRNAs targeting either *Mettl3* or *Mettl14*

genes (Supplementary Fig.3D). To expand these observations genome-wide, Gene-set Enrichment Analysis (GSEA) of pluripotency-related genes and developmental regulators was performed assessing differential gene expressions in kd versus control cells. Developmental regulators were defined as the ~2800 bivalent genes whose promoters exhibit both eu- and hetero-chromatin markers in mESCs¹³, and 145 genes present in the Oct4-centered protein-protein interaction (PPI) network were used as pluripotency-related genes¹⁴. GSEA analysis showed enrichment of developmental regulators in both Mettl3 and Mettl14 kd versus control cells (left panels of Fig. 3F and Supplementary Fig.3E), while pluripotency-related genes showed negative enrichment (right panels of Fig. 3F and Supplementary Fig.3E). Taken together, these studies suggest that m⁶A methylation is essential to maintain mESCs at their ground state.

m⁶A is highly enriched near transcript stop codon^{2,3}. Thus we conducted ³⁵S-pulse labeling in kd and control mESCs to determine whether depletion of modification impaired protein synthesis and detected no significant changes (Supplementary Fig.4A and Supplementary Fig.4B). However, analysis of potential correlation between RNA methylation and gene expression levels indicated that loss of m⁶A methylation following Mettl3 kd or Mettl14 kd was more significantly associated with gene up- than down-regulation (Fig. 4A and Supplementary Fig.4C). Multiple cellular mechanisms can contribute to increased RNA levels. Since m⁶A is an internal modification that is enriched at 3-UTR^{2,3}, we checked whether m⁶A affects mRNA decay rate by measuring RNA levels from actinomycin D (ActD) treated scramble and kd mESCs. Significantly, Mettl targets showed a ~23% increase in the maximum cumulative RNA stability in kd cells compared to the controls (Fig. 4B, left and mid-panels, and Supplementary Table2) from 4 to 8 hrs after ActD treatment, in contrast to only 9% for the non-targets (Fig. 4B, right panel, and Supplementary Table2), suggesting that m⁶A modification accelerates transcript decay.

Next we asked whether developmental regulators or pluripotency-related genes are subject to m⁶A regulation. Enrichment analysis showed that compared to pluripotency-related genes, developmental regulators were much more significantly enriched in Mettl3 and Mettl14 targets (Fig. 4C). meRIP RT-qPCR of both gene subclasses confirmed that transcripts of many developmental regulators were more highly enriched in m⁶A methylation than were transcripts encoding housekeeping genes such (ActB or GapDH) or the pluripotency factors (such as Pou5f1 or Nanog) (Fig. 4D). Bivalent genes identified as Mettl3 or Mettl14 targets also showed a more significant increase in RNA stability than did pluripotency genes following kd of either protein (Fig. 4E), suggesting that m⁶A methylation destabilizes developmental regulators. To further understand the dynamics of m⁶A modification, we measured m⁶A levels during mESC differentiation. Cells at days 6 or 12 of differentiation showed overall m⁶A levels (Fig. 4F) or Mettl14 expression (Fig. 4G) comparable to undifferentiated mESCs, although we detected a moderate decrease in Mettl3 expression in differentiated cells (Fig. 4G). Interestingly, gene-specific meRIP-qPCR showed significantly decreased m⁶A levels in 5 of 8 developmental regulators examined in day12 cells (Fig. 4H, grey area). In contrast, all 3 pluripotency-related genes showed unchanged or increased m⁶A levels (Fig.4H). These data indicate that developmental regulators are subject to m⁶A regulation in mESCs.

To assess molecular mechanisms underlying m⁶A methylation-mediated RNA decay, we focused on the well-established RNA stabilizer protein HuR^{15,16}, which binds to the U-rich regions at the 3'-UTR of thousands of transcripts^{17,18}. Enrichment analysis suggested that Mettl targets exhibiting HuR binding sites showed significantly increased RNA stability (Fig. 5A) relative to those without HuR sites. We then asked whether the presence of m⁶A affects HuR binding to RNA. To do so, we incubated purified HuR protein (Supplementary Fig.4D) with fragmented mRNA extracted from scramble, Mettl3 kd, and Mettl14 kd cells (Fig. 5B, left panel) and performed RNA electrophoretic mobility shift assay. We observed increased HuR binding to demethylated mRNA extracted from kd compared to control cells (Fig. 5B, mid-panels). However, work reported by Dominissini *et al*³ indicated that HuR interacts with an RNA probe containing m⁶A *in vitro*. To assess this potential discrepancy, we examined the ~60 bp RNA probe used in that study in which m⁶A is immediately adjacent to the HuR binding site. We reasoned that endogenous m⁶A and HuR sites may not always co-localize since predicted m⁶A and HuR binding sites RNA motifs differ substantially and hypothesize that the spacing of HuR and m⁶A sites may affect their interaction. Thus, we designed RNA probes with no spacer (Fig. 5C, RNA probes 0A and 0m⁶A) or a 12-nt spacer (Fig. 5C, RNA probes 12A and 12m⁶A) between A/m⁶A and HuR sites. Consistent with Dominissini *et al*³, we observed significantly increased HuR binding to the 0m⁶A versus 0A RNA probes (Fig. 5B, right panel). By contrast, we observed moderately decreased HuR binding in the presence of the 12 nt spacer (Fig. 5B, right panel), suggesting spatial constraints govern m⁶A and HuR binding.

To analyze potential negative interaction between HuR and m⁶A *in vivo*, we chose three representative genes for validation: Pou5f1, Otx2, and Igfbp3. Pou5f1 transcripts lack m⁶A, while bivalent Otx2 and Igfbp3 are Mettl3 and Mettl14 targets that showed increased expression in kd cells (Fig. 3E and Supplementary Fig.3C). The Igfbp3 3'-UTR, however, exhibits a HuR binding motif, while that of Otx2 does not. Assessment of the m⁶A methylation status of Otx2 and Igfbp3 showed that both transcripts were demethylated in Mettl kd cells (Supplementary Fig.4E). RIP analysis indicated increased HuR binding at Igfbp3 3'-UTR in Mettl3 or Mettl14 kd cells, but not of Otx2 or Pou5f1 (Fig. 5D), suggesting that de-methylation accompanies HuR binding. Importantly, increased HuR binding accompanied increased stability of Igfbp3 RNA but not of Otx2 and Pou5f1 in kd cells (Fig. 5E). To test whether HuR mediated that increased stability, we first confirmed that we could target HuR efficiently with siRNA in Mettl3 or Mettl14 kd cells (Supplementary Fig.4F). We then measured Igfbp3 RNA stability in these cells in the absence of HuR and observed that stability was restored to control levels (Fig. 5E). This result was confirmed by specifically decreased Igfbp3 expression in mESCs depleted of HuR (Fig. 5F). Overall, our *in vivo* analysis suggests that loss of m⁶A methylation enhances HuR RNA binding to increase RNA stability.

HuR binding reportedly increases RNA stability by blocking microRNA targeting^{15,16}. Igfbp3, for example, is a direct target of several microRNAs^{19,20}. Therefore, we carried out RIP with Argonaute 2 (Ago2), a key factor of the RNA-induced silencing complex (RISC), in Mettl3 or Mettl14 kd cells. We observed a ~25-40% decrease in Ago2 binding to the Igfbp3 3'-UTR, but little change to Pou5f1, which is not a methylation target and displays

equivalent HuR binding in kd versus control cells (Fig. 5G). To understand whether this mechanism applies to other RNAs, we evaluated *Mettl3* or *Mettl14* targets that show increased RNA stability and expression in relation to Ago2-bound mRNAs in kd versus control mESCs, as defined by a previous CLIP-seq study²¹. Interestingly, we observed specific enrichment of Ago2-bound *Mettl3/14* targets (Fig. 5H) but not targets lacking Ago2 binding. These results suggest that the HuR/microRNA pathway mediates m⁶A-regulated RNA stability.

We propose a model in which the presence of m⁶A methylation on some transcripts in mESCs, particularly those encoding developmental regulators, blocks HuR binding and destabilizes them, thereby maintaining the mESC ground state (Fig. 5I). Our work suggests that m⁶A methylation is an essential RNA regulatory mechanism in mammalian cells.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Dr. Miles Wilkinson and all members of his laboratory for many valuable discussions; the Mass Spectrometry, Metabolomics, and Proteomics Facility at the University of Illinois at Chicago for measuring m⁶A/A ratios; Subramaniam Shyamala Govindarajan from the Analytical Genomics core facility at the Sanford Burnham Medical Institute (Lake Nona) for performing the microarray analysis; and Phillip Ordoukhanian and Steven Robert Head from the Scripps Research Institute for high throughput sequencing analysis. This work is supported by a CIRM Training Grant TG2-01162 (Y.W.), an AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research 12-20-10-ZHAO (J.C.Z.), the Ontario Research Fund - Global Leader (Round 2) and Natural Sciences and Engineering Research Council (NSERC) (Z.Z.), and an NSERC Canada Graduate Scholarship and Ontario Graduate Scholarship (Y.L.). M.D.P. is an American Cancer Society Research Scholar (RSG-11-224-01-DMC). Z.Z. would like to dedicate this paper to the memory of S. Z.

REFERENCES

1. Jia G, Fu Y, He C. Reversible RNA adenosine methylation in biological regulation. *Trends in genetics* : TIG. 2013; 29:108–115. doi:10.1016/j.tig.2012.11.003. [PubMed: 23218460]
2. Meyer KD, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell*. 2012; 149:1635–1646. doi:10.1016/j.cell.2012.05.003. [PubMed: 22608085]
3. Dominissini D, et al. Topology of the human and mouse m⁶A RNA methylomes revealed by m⁶A-seq. *Nature*. 2012; 485:201–206. doi:10.1038/nature11112. [PubMed: 22575960]
4. Zheng G, et al. ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility. *Molecular cell*. 2013; 49:18–29. doi:10.1016/j.molcel.2012.10.015. [PubMed: 23177736]
5. Jia G, et al. N⁶-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nature chemical biology*. 2011; 7:885–887. doi:10.1038/nchembio.687. [PubMed: 22002720]
6. Bokar JA, Shambaugh ME, Polayes D, Matera AG, Rottman FM. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N⁶-adenosine)-methyltransferase. *RNA*. 1997; 3:1233–1247. [PubMed: 9409616]
7. Clancy MJ, Shambaugh ME, Timpte CS, Bokar JA. Induction of sporulation in *Saccharomyces cerevisiae* leads to the formation of N⁶-methyladenosine in mRNA: a potential mechanism for the activity of the *IME4* gene. *Nucleic acids research*. 2002; 30:4509–4518. [PubMed: 12384598]
8. Agarwala SD, Blitzblau HG, Hochwagen A, Fink GR. RNA methylation by the MIS complex regulates a cell fate decision in yeast. *PLoS genetics*. 2012; 8:e1002732. doi:10.1371/journal.pgen.1002732. [PubMed: 22685417]

9. Zhong S, et al. MTA is an Arabidopsis messenger RNA adenosine methylase and interacts with a homolog of a sex-specific splicing factor. *The Plant cell*. 2008; 20:1278–1288. doi:10.1105/tpc.108.058883. [PubMed: 18505803]
10. Bodi Z, et al. Adenosine Methylation in Arabidopsis mRNA is Associated with the 3' End and Reduced Levels Cause Developmental Defects. *Frontiers in plant science*. 2012; 3:48. doi:10.3389/fpls.2012.00048. [PubMed: 22639649]
11. Bujnicki JM, Feder M, Radlinska M, Blumenthal RM. Structure prediction and phylogenetic analysis of a functionally diverse family of proteins homologous to the MT-A70 subunit of the human mRNA:m(6)A methyltransferase. *Journal of molecular evolution*. 2002; 55:431–444. doi:10.1007/s00239-002-2339-8. [PubMed: 12355263]
12. Petrossian TC, Clarke SG. Uncovering the human methyltransferasome. *Molecular & cellular proteomics : MCP*. 2011; 10 M110 000976, doi:10.1074/mcp.M110.000976.
13. Ku M, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. *PLoS genetics*. 2008; 4:e1000242. doi:10.1371/journal.pgen.1000242. [PubMed: 18974828]
14. van den Berg DL, et al. An Oct4-centered protein interaction network in embryonic stem cells. *Cell stem cell*. 2010; 6:369–381. doi:10.1016/j.stem.2010.02.014. [PubMed: 20362541]
15. Srikantan S, Tominaga K, Gorospe M. Functional interplay between RNA-binding protein HuR and microRNAs. *Current protein & peptide science*. 2012; 13:372–379. [PubMed: 22708488]
16. Kundu P, Fabian MR, Sonenberg N, Bhattacharyya SN, Filipowicz W. HuR protein attenuates miRNA-mediated repression by promoting miRISC dissociation from the target RNA. *Nucleic acids research*. 2012; 40:5088–5100. doi:10.1093/nar/gks148. [PubMed: 22362743]
17. Kishore S, et al. A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. *Nature methods*. 2011; 8:559–564. doi:10.1038/nmeth.1608. [PubMed: 21572407]
18. Lebedeva S, et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. *Molecular cell*. 2011; 43:340–352. doi:10.1016/j.molcel.2011.06.008. [PubMed: 21723171]
19. Le MT, et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. *PLoS genetics*. 2011; 7:e1002242. doi:10.1371/journal.pgen.1002242. [PubMed: 21935352]
20. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. *Cancer research*. 2007; 67:10117–10122. doi:10.1158/0008-5472.CAN-07-2544. [PubMed: 17974952]
21. Leung AK, et al. Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs. *Nature structural & molecular biology*. 2011; 18:237–244. doi:10.1038/nsmb.1991.




Figure 1. Mettl3 and Mettl14 are required for m⁶A formation *in vitro* and *in vivo*

A. Schematic drawing showing predicted MTase domains of mouse Mettl3 (Accession: NP_062695.2) and Mettl14 (Accession: NP_964000.2) proteins. Numbers represent amino acid numbers. **B.** RT-qPCR (left) and western blot (right) showing Mettl3 (left panel) and Mettl14 (right panel) expression in mESC clones stably expressing shRNAs targeting each. GapDH serves as a loading control in the western blot. Scr: scramble; shM3, shRNA against Mettl3; shM14, shRNA against Mettl14. The original gel is shown in Supplementary Fig.5. **C.** Ethidium bromide staining (left panel) and m⁶A immunoblot (right panel) of DNA-free, rRNA-free Poly(A)+ RNA from Mettl3 kd, Mettl14 kd, and control cells. **D.** Measurement of percentage of m⁶A/A ratio by MS. **E.** Flag, Mettl3 or Mettl14 western immunoblots of proteins purified from lysates of HEK293 cells overexpressing flag-tagged Mettl3, Mettl14, or luciferase using M2 beads. Luc, luciferase; M3, Mettl3; M14, Mettl14. The original gel is shown in Supplementary Fig.5. **F.** CPM counts of RNA probes extracted after an *in vitro* methylation assay. **G.** CPM counts of excised m⁶A spots from digested RNA probes used in the methylation assay. Error bars from panels B and F-G represent means ± SEM from 3 separate experiments, except M3 in panel G where n=7. One-tailed Student's *t*-test, **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001 vs. scramble control. Scr: scramble control.




Figure 2. *Mettl3* and *Mettl14* interact and regulate each other's stability

A. meRIP-seq analysis of a *Sox17* transcript showing loss of m⁶A methylation in both *Mettl3* kd and *Mettl14* kd cells. Yellow highlighting, peak location. Scr: scramble; shM3, shRNA against *Mettl3*; shM14, shRNA against *Mettl14*. **B.** Venn diagram showing overlap of *Mettl3* and *Mettl14* targets. **C.** *Mettl3* or *Mettl14* western immunoblots of endogenous proteins co-IP'd using antibodies against *Mettl3* or *Mettl14*, or IgG in mESC lysates. M3, *Mettl3*; M14, *Mettl14*. The original gel is shown in Supplementary Fig.5. **D.** Western blot analysis of *Mettl3* and *Mettl14* protein levels in *Mettl3* kd and *Mettl14* kd mESCs, respectively. The original gel is shown in Supplementary Fig.5. **E.** RT-qPCR analysis of *Mettl3* and *Mettl14* RNA levels in *Mettl3* kd and *Mettl14* kd mESCs, respectively. Error bars from panel E represent means \pm SEM from 3 separate experiments. One-tailed Student's *t*-test, ***P* < 0.01, ****P* < 0.001 vs. scramble control. Scr: scramble. **F.** GO analysis of 4395 shared *Mettl3* and *Mettl14* targets. Error bars from panel E represent means \pm SEM from 3 separate experiments. One-tailed Student's *t*-test, ***P* < 0.01, ****P* < 0.001 vs. scramble control. Scr: scramble.




Figure 3. *Mettl3* or *Mettl14* knockdown mESCs lose self-renewal capability

A. Phase contrast microscopy showing colony morphology of kd versus control mESC cells. Scr: scramble; shM3, shRNA against *Mettl3*; shM14, shRNA against *Mettl14*. **B.** Growth curve assessing cell proliferation kinetics of kd versus control cells. P values are generated by two-way ANOVA. **C.** Quantification of AP-positive colonies. **D.** Heat map analysis based on microarray comparison of gene expression in kd and control cells. **E.** RT-qPCR analysis of pluripotency (left) and differentiation (right) genes in kd versus control cells. **F.** GSEA analysis on enrichment of developmental regulators (left) and pluripotency-related genes (right) in *Mettl3* kd versus control cells. A False Discovery Rate (FDR) of <0.178 was calculated for bivalent genes and $FDR < 0$ for pluripotency-related genes. Note that $FDR < 0.25$ is statistically significant for GSEA analysis: www.broadinstitute.org/gsea/doc/GSEAUUserGuideFrame.html. Scale bars, 100 μ m. Error bars from panels B-C and E represent mean \pm SEM from 3 separate experiments. One-tailed Student's *t*-test, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ vs. scramble control. Scr: scramble.




Figure 4. m⁶A modification regulates mRNA stability

A. Enrichment of up- or down- regulated Mettl3 and Mettl14 targets in kd versus control cells. Arrows indicate up- or down regulation of gene expression. Scr: scramble; shM3, shRNA against Mettl3; shM14, shRNA against Mettl14. **B.** Comparison of cumulative transcript abundance in cells treated with Actinomycin D for 0, 4, and or 8 hrs by microarray analysis. RNAs from 0 hr serves as base-line. KS test, $p < 2.2e-16$ comparing the changes in relative RNA levels from 4 to 8 hrs between Mettl targets and non-targets in both Mettl3 kd and Mettl14 kd cells. **C.** Enrichment of bivalent and pluripotency (Oct4 PPI) genes in shared Mettl3 and Mettl14 targets. **D.** meRIP-qPCR of specific bivalent and pluripotency genes (grey area). **E.** Enrichment of Mettl3 and Mettl14 targets showing increased RNA stability in kd cells among bivalent and pluripotency genes. **F.** Measurement of a percentage of m⁶A/A ratio by MS in undifferentiated (day 0), day6, and day 12 differentiated mESCs. **G.** RT-qPCR of Mettl3, Mettl14, and Rex1 expression in undifferentiated and differentiated mESCs. **H.** meRIP-qPCR of specific bivalent (gray area) and pluripotency genes in mESCs during differentiation. Error bars from panels D and G-H represent means \pm SEM from 3 separate experiments. One-tailed Student's *t*-test, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ vs. scramble control. Scr: scramble.




Figure 5. The HuR-microRNA pathway functions in m⁶A methylation-mediated RNA stability

A. Enrichment of genes showing increased RNA stability following Mettl3 or Mettl14 kd among all shared Mettl3 and Mettl14 targets and among targets with and without canonical HuR binding sites in their 3'-UTR regions. M3, Mettl3; M14, Mettl14. **B.** Left panel, denaturing PolyAcrylamide Gel Electrophoresis (PAGE) showing the size of fragmented, DNase-treated, rRNA-free mRNAs extracted from scramble and kd cells; mid-panel, non-denaturing PAGE showing differential binding of HuR to RNAs probes from left panel. Scr: scramble control, shM14, shRNA against Mettl14, shM3, shRNA against Mettl3. NP: no protein added. Right panel, non-denaturing PAGE showing differential binding of HuR to RNA probes enlisted in C. **C.** RNA probes with the canonical UUUUU HuR binding site located either next to A (0A) or m⁶A (0m⁶A) or separated by a 12-nucleotide spacer (12A and 12m⁶A). **D.** HuR RIP-qPCR of Pou5f1, Igfbp3, and Otx2 from kd versus control cells. **E.** RT-qPCR of Pou5f1, Igfbp3, and Otx2 in Actinomycin D-treated kd cells. In the case of Igfbp3, cells are also treated with and without siRNA targeting HuR. P values are generated using two-way ANOVA. **F.** RT-qPCR of HuR, Igfbp3, Otx2, and Pou5f1 in mESC with depleted HuR. shHuR#1-3: shRNAs against HuR. **G.** Argonaute 2 (Ago2) RIP-qPCR of Igfbp3 and Pou5f1 RNAs from kd versus control cells. **H.** Enrichment of genes showing increased RNA stability and expression among shared Mettl3 and Mettl14 targets. Targets

are classified by whether they display Ago2 binding sites. **I. Model:** In wildtype mESCs, Mettl3 and Mettl14 methylate RNA synergistically and m⁶A methylation on some transcripts, particularly those encoding developmental regulators, blocks HuR binding, resulting in transcript destabilization. In Mettl3 and Mettl14 kd cells, loss of m⁶A allows HuR-mRNA interaction and attenuation of microRNA targeting, enhancing stability of transcripts especially those encoding developmental regulators, and promoting loss of the mESC ground state. A potentially methylated A is shown in red. Error bars from panels D-G represent means ± SEM from 3 separate experiments. One-tailed Student's *t*-test, **P* < 0.05, ** *p* < 0.01, *****P* < 0.0001 vs. scramble control. Scr: scramble.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript